Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine /atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)
- Author
- HOBBS, F. D. Richard1 ; GENSINI, Gianfranco2 ; METCALFE, Michael13 ; MARQUES DA SILVA, Pedro14 ; MANCINI, G. B. John3 ; MANOLIS, Athanasios J4 5 ; BAUER, Beverly6 ; BÖHLER, Steffen7 ; GENEST, Jacques8 ; FELDMAN, Ross10 9 ; HARVEY, Peter11 ; JENSSEN, Trond G12
[1] Primary Cave Clinical Sciences Building, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
[2] University of Florence, Florence, Italy
[3] University of British Columbia, Vancouver, British Columbia, Canada
[4] Hypertension and Heart Failure Clinic, Tzanio Hospital, Piraeus, Greece
[5] Boston University, School of Medicine, Boston, United States
[6] Pfizer Canada Inc, Kirkland, Quebec, Canada
[7] Pfizer GmbH, Mooswaldallee 1, Freiburg, Germany
[8] McGill University Health Center, Montreal, Quebec, Canada
[9] Department of Medicine, University of Western Ontario, London, United Kingdom
[10] Department of Physiology and Pharmacology, University of Western Ontario, London, United Kingdom
[11] Crouch Oak Family Practice, Addlestone, Surrey, United Kingdom
[12] University of Trømso, Senior Consultant, Department of Medicine, Section of Nephrology, Rikshospitalet, University of Oslo, Oslo, Norway
[13] Pfizer Ltd., Walton Oaks, Walton-on-the Hill, Surrey, United Kingdom
[14] Hypertension and Dyslipidemia Clinic, Nucleo de Investigaçao Arterial Hospital de Santa Maria, Rua de Santa Marta, Lisboa, Portugal
the JEWEL Study Group - Source
International journal of cardiology. 2006, Vol 110, Num 2, pp 242-250, 9 p ; ref : 42 ref
- CODEN
- IJCDD5
- ISSN
- 0167-5273
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Elsevier Science, Shannon
- Publication country
- Ireland
- Document type
- Article
- Language
- English
- Author keyword
- Amlodipine Atorvastatin Cardiovascular disease Dyslipidemia Hypertension Risk factors
- Keyword (fr)
- Amlodipine Appareil circulatoire pathologie Appareil circulatoire Athérosclérose Atorvastatine Concentration Conception Dyslipémie Efficacité Exploration Facteur risque Formulation Hypertension artérielle International Lipide Pression artérielle Pression sanguine Programme Risque Réduction Sang Métabolisme pathologie Vaisseau sanguin pathologie
- Keyword (en)
- Amlodipine Cardiovascular disease Circulatory system Atherosclerosis Atorvastatin Concentration Design Dyslipemia Efficiency Exploration Risk factor Formulation Hypertension International Lipids Arterial pressure Blood pressure Program Risk Reduction Blood Metabolic diseases Vascular disease
- Keyword (es)
- Amlodipino Aparato circulatorio patología Aparato circulatorio Ateroesclerosis Atorvastatina Concentración Diseño Dislipemia Eficacia Exploración Factor riesgo Formulación Hipertensión arterial Internacional Lípido Presión arterial Presión sanguínea Programa Riesgo Reducción Sangre Metabolismo patología Vaso sanguíneo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12B Blood and lymphatic vessels / 002B12B01 Atherosclerosis (general aspects, experimental research)
- Discipline
- Cardiology. Circulatory system
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17848040
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.ijcard.2005.10.017 
https://dx.doi.org/10.1016/j.ijcard.2005.10.017
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:3:\"110\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"242\";s:8:\"\u0000*\u0000epage\";s:3:\"250\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HOBBS\";s:10:\"\u0000*\u0000aufirst\";s:13:\"F. D. Richard\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:19:\"GENSINI, Gianfranco\";i:1;s:17:\"METCALFE, Michael\";i:2;s:23:\"MARQUES DA SILVA, Pedro\";i:3;s:19:\"MANCINI, G. B. John\";i:4;s:21:\"MANOLIS, Athanasios J\";i:5;s:14:\"BAUER, Beverly\";i:6;s:16:\"B\u00d6HLER, Steffen\";i:7;s:15:\"GENEST, Jacques\";i:8;s:13:\"FELDMAN, Ross\";i:9;s:13:\"HARVEY, Peter\";i:10;s:16:\"JENSSEN, Trond G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:3:\"110\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"242\";s:8:\"\u0000*\u0000epage\";s:3:\"250\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HOBBS\";s:10:\"\u0000*\u0000aufirst\";s:13:\"F. D. Richard\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:19:\"GENSINI, Gianfranco\";i:1;s:17:\"METCALFE, Michael\";i:2;s:23:\"MARQUES DA SILVA, Pedro\";i:3;s:19:\"MANCINI, G. B. John\";i:4;s:21:\"MANOLIS, Athanasios J\";i:5;s:14:\"BAUER, Beverly\";i:6;s:16:\"B\u00d6HLER, Steffen\";i:7;s:15:\"GENEST, Jacques\";i:8;s:13:\"FELDMAN, Ross\";i:9;s:13:\"HARVEY, Peter\";i:10;s:16:\"JENSSEN, Trond G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:3:\"110\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"242\";s:8:\"\u0000*\u0000epage\";s:3:\"250\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HOBBS\";s:10:\"\u0000*\u0000aufirst\";s:13:\"F. D. Richard\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:19:\"GENSINI, Gianfranco\";i:1;s:17:\"METCALFE, Michael\";i:2;s:23:\"MARQUES DA SILVA, Pedro\";i:3;s:19:\"MANCINI, G. B. John\";i:4;s:21:\"MANOLIS, Athanasios J\";i:5;s:14:\"BAUER, Beverly\";i:6;s:16:\"B\u00d6HLER, Steffen\";i:7;s:15:\"GENEST, Jacques\";i:8;s:13:\"FELDMAN, Ross\";i:9;s:13:\"HARVEY, Peter\";i:10;s:16:\"JENSSEN, Trond G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:3:\"110\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"242\";s:8:\"\u0000*\u0000epage\";s:3:\"250\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HOBBS\";s:10:\"\u0000*\u0000aufirst\";s:13:\"F. D. Richard\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:19:\"GENSINI, Gianfranco\";i:1;s:17:\"METCALFE, Michael\";i:2;s:23:\"MARQUES DA SILVA, Pedro\";i:3;s:19:\"MANCINI, G. B. John\";i:4;s:21:\"MANOLIS, Athanasios J\";i:5;s:14:\"BAUER, Beverly\";i:6;s:16:\"B\u00d6HLER, Steffen\";i:7;s:15:\"GENEST, Jacques\";i:8;s:13:\"FELDMAN, Ross\";i:9;s:13:\"HARVEY, Peter\";i:10;s:16:\"JENSSEN, Trond G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/j.ijcard.2005.10.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:9:\"\u0000*\u0000jtitle\";s:35:\"International journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Int. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:3:\"110\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"242\";s:8:\"\u0000*\u0000epage\";s:3:\"250\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-5273\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HOBBS\";s:10:\"\u0000*\u0000aufirst\";s:13:\"F. D. Richard\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:19:\"GENSINI, Gianfranco\";i:1;s:17:\"METCALFE, Michael\";i:2;s:23:\"MARQUES DA SILVA, Pedro\";i:3;s:19:\"MANCINI, G. B. John\";i:4;s:21:\"MANOLIS, Athanasios J\";i:5;s:14:\"BAUER, Beverly\";i:6;s:16:\"B\u00d6HLER, Steffen\";i:7;s:15:\"GENEST, Jacques\";i:8;s:13:\"FELDMAN, Ross\";i:9;s:13:\"HARVEY, Peter\";i:10;s:16:\"JENSSEN, Trond G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"IJCDD5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:350:\"Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine \/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
